Epinephrine pen maker offers discounts after alleged price hikingBMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i4730 (Published 31 August 2016) Cite this as: BMJ 2016;354:i4730
- Michael McCarthy
Mylan NV, which makes the epinephrine auto-injection device EpiPen, has announced that it will expand its discount and coupon programs for uninsured and under-insured patients and has promised to sell an identical generic device at half the price of the branded product, after criticism of its pricing policy.
However, critics remain unsatisfied and have called for government action to force Mylan to lower its prices further.
“The company must roll back its unjustified and outrageous price increases,” said Robert Weissman, president of the consumer group Public Citizen. On 30 August, Public Citizen and several other organizations delivered petitions with a reported 700 000 signatures, protesting against the drug’s price, to …
Log in using your username and password
Log in through your institution
Sign up for a free trial